TRex Bio (TRXB) Stock Analysis
NASDAQHealthcareMedical - Pharmaceuticals
Track TRXB in your portfolio for free · Portfolio tracker
What TRex Bio does
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.
Key metrics
ETFs linked to TRXB
Broad-market and Healthcare sector ETFs an investor holding TRex Bio is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how TRXB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze TRXB in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for TRex Bio?
- TRex Bio trades under the ticker TRXB on NASDAQ.
- Which exchange is TRXB listed on?
- TRXB is listed on NASDAQ.
- What sector does TRex Bio operate in?
- TRex Bio is classified in the Healthcare sector (Medical - Pharmaceuticals industry).
- How can PortView help analyze TRXB in a portfolio?
- PortView shows TRXB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.